INTIVA BioPharma Inc. is a potentially disruptive drug development company
focused on cannabinoid-based pharmaceutical solutions.
The Company is researching and developing drug and cannabinoid molecules
for various medical conditions and diseases. ArcView Market Research estimates that
America's pharmaceutical cannabis sector could reach over $23 billion by 2020.
INTIVA’S DRUG DEVELOPMENT ACTIVITIES
INTIVA’s drug development strategy consists of:
1. The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations;
2. Conducting “freedom to operate” investigations on these conditions;
3. The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents;
4. Identifying the regulatory pathway with the U.S. Food and Drug Administration (FDA); and
5. Proceeding with clinical studies and clinical trials under FDA protocols for submission to obtain approval for the drug(s).
Because of the federal illegality of cannabis in the United States,
INTIVA is focusing its initial drug development using synthetic cannabinoids,
some of which are approved by the FDA for various medical conditions.
Synthetic cannabinoids generally simplify research development in the U.S.
However, INTIVA also intends to proceed with trials using plant-derived cannabinoids.
Because of the difficulty in proceeding with those trials in the United States,
the INTIVA will likely proceed with those trials in jurisdictions where the research is legal, such as Israel.
Jeffrey Friedland, Chief Executive Officer, and Director
Jeffrey Friedland is the Chief Executive Officer of the Company. He is also the Chief Executive Officer and Chairman of the Board of INTIVA Inc., https://www.intiva.us/ and has served in those positions since the inception of the Company in February 2014. He also is a co-founder of the INTIVA Inc.
Mr. Friedland is a founder of Israel-based, Israel Plant Sciences Ltd., a company that is participating in Israel’s innovative agriculture and medicinal plant sectors and other agricultural related technologies, with a primary focus on cannabis. Mr. Friedland is also a director of CannRx a US-based company with its principal operations in Israel that is researching the medical benefits of cannabis-based pharmaceuticals.
In addition, Jeff is on the Board of Advisors of OWC Pharmaceutical Research Corp. http://www.owcpharma.com/ [symbol : OWCP] an Israeli Medical Research company doing real Marajuana Medical Research and Clinical Trials in Israel. Link to Clinical Trial ... http://tinyurl.com/ycgallvw
In his recently-published second book, "Marijuana: the World's Most Misunderstood Plant",
Mr. Friedland dives into the world of marijuana, discussing the history of the plant,
what we know and what we still hope to discover.
View it on Amazon Books ... http://tinyurl.com/ybsttnwn
Since 1981, Mr. Friedland has provided investment banking, merchant banking, and corporate finance advisory services to hundreds of privately-held and listed companies worldwide. These services have included obtaining venture capital and private equity capital, mergers and acquisitions, and assistance to companies regarding financing their growth and becoming stock market listed on stock exchanges worldwide. Mr. Friedland has been the chief executive officer and a director of a NASDAQ-listed financial services company, a director, and chairman of the audit committee of a New York Stock Exchange-listed company, and chairman of a company listed on the EU-regulated market of the Frankfurt Stock Exchange.
He is an author, speaker and thought leader on emerging markets, the global economy, and the cannabis industry. He has been featured or quoted in numerous publications including the Wall Street Journal, Reuters, the New York Times, USA Today, the South China Morning Post, the Guam Daily Post, Bloomberg, the Forward, the Jewish Week, Quartz, the Jakarta Globe, Israel Daily Television, BreitBart, NBC.com and Forbes.
Jeffrey Friedland's personal website for his link to his book, his articles and videos: www.jeffreyfriedland.com